J. Joseph Kim, Ph.D.
President, Chief Executive Officer, Director
JOSEPH KIM was appointed President and CEO of Inovio Pharmaceuticals in June 2009. Dr. Kim co-founded VGX Pharmaceuticals, a synthetic vaccine company, in 2000 to develop intellectual property related to immunotherapeutics licensed from the University of Pennsylvania. He led that company for nine years and combined VGX with Inovio Biomedical in 2009 to form Inovio Pharmaceuticals. Previously, Dr. Kim was a senior vaccine developer at Merck & Co. where he successfully led efforts in manufacturing and process development for several FDA-approved products for hepatitis and developmental vaccines and therapeutics for HIV/AIDS.
Dr. Kim earned a Bachelor of Science degree in Chemical Engineering and Economics from the Massachusetts Institute of Technology (MIT), where he was a U.S. Senate Honors Scholar. He holds a PhD in Biochemical Engineering from the University of Pennsylvania and a Master of Business Administration degree in Finance from the Wharton School. Dr. Kim has published more than 100 peer-reviewed scientific papers, holds numerous patents and sits on several editorial boards and review panels.
Dr. Kim has been recognized with numerous honors in the past several years, including:
Chief Financial Officer
PETER KIES has been Chief Financial Officer of Inovio since 2002. During the prior 16 years, Mr. Kies acquired broad expertise in the functional and strategic management of biotechnology and high technology companies across the full spectrum of corporate growth, from IPO to profitability. He was previously Chief Financial Officer at Newgen Results Corporation and held positions at Cytel Corporation and Ernst & Young, LLP. Mr. Kies holds a Bachelor of Science degree in Business Administration from United States International University in San Diego, California.
Niranjan Y. Sardesai, Ph.D.
Chief Operating Officer
NIRANJAN Y. SARDESAI was appointed Chief Operating Officer of Inovio in January 2012. He served as the Company’s Senior Vice President of Research and Development following the June 2009 merger with VGX Pharmaceuticals, at which company he held the same position. Dr. Sardesai was previously the founder and President of NVision Consulting Inc., a firm providing strategic counsel to entrepreneurial life sciences companies. He served as Director of Research and Development at Fujirebio Diagnostics, Inc., where he oversaw research and development and expansion of the company’s oncology portfolio. Products developed under his leadership include groundbreaking new tests for mesothelioma (MESOMARK™), bladder cancer and a multi-marker test for ovarian cancer.
Dr. Sardesai received a Doctor of Philosophy degree in Chemistry from the California Institute of Technology and a Master of Business Administration from the Wharton School of the University of Pennsylvania, where he was the recipient of the Shils-Zeidman Award in Entrepreneurship. He completed fellowships at Scripps Research Institute and the Massachusetts Institute of Technology (MIT). Dr. Sardesai received his Bachelor and Master of Science degrees in Chemistry from the Indian Institute of Technology, Bombay. He has authored over 40 peer-reviewed publications, presented at over 75 invited lectures and presentations, and filed several patents.
Mark L. Bagarazzi, M.D.
Chief Medical Officer
MARK L. BAGARAZZI joined Inovio in January 2010 from Merck & Co., where he was Director of Worldwide Regulatory Affairs, responsible for vaccines and biologics. Dr. Bagarazzi led ongoing vaccine product and regulatory development of Merck’s ZOSTAVAX®, the leading vaccine for shingles. He was responsible for global regulatory activities related to Merck vaccine candidates for the prevention of HIV/AIDS. He also successfully led the regulatory process culminating in FDA approval of RotaTeq®, Merck’s vaccine against rotavirus. Prior to joining Merck in 2001, he was director of the HIV/AIDS program for St. Christopher’s Hospital for Children in Philadelphia. Dr. Bagarazzi is a guest lecturer on vaccines and immunotherapeutics at the University of Pennsylvania School of Medicine. Previously he was an assistant professor of pediatrics at Drexel College of Medicine and a guest lecturer at Johns Hopkins University.
Dr. Bagarazzi holds a Bachelor of Science degree in electrical engineering, magna cum laude, from the New Jersey Institute of Technology and received his MD degree with honors from the University of Medicine and Dentistry of New Jersey. He holds several patents and has co-authored dozens of scientific papers focused on the subject of DNA vaccines that have been published in peer-reviewed medical journals.
Vice President, Engineering Operations
STEPHEN KEMMERRER is responsible for engineering, manufacturing, materials, distribution and all quality and regulatory aspects of electroporation instruments used in the delivery of Inovio’s synthetic vaccines. Prior to joining Inovio in 2007, he held senior engineering and management positions at K2 Engineering, CancerVax and BioSite. In 2002, he co-founded Sorrento BioSurgical, a start-up based on human tissue mesh technology. Previously, he was Director of Engineering at Advanced Tissue Sciences, Engineering Manager at Pacific Device and Project Engineer at Hughes Aircraft Space and Communications. Mr. Kemmerrer holds a BS in Mechanical Engineering from UC Berkeley and an MBA from San Diego State University.
Thomas Kim, Esq.
General Counsel and Corporate Secretary
THOMAS KIM is an experienced corporate attorney and a registered patent attorney, and has served as the senior in-house counsel for Inovio, and its predecessor companies, since 2007. He leads the legal department as General Counsel, and he also serves as the Corporate Secretary. At Inovio, he has built an intellectual property department from the ground up, and has overseen the integration of portfolios from several M&A deals. In addition, Mr. Kim works with senior management and the Board on a regular basis on various corporate matters, including mergers and acquisitions, agreements, corporate financing, employment, and compliance and risk management.
Mr. Kim has counseled pharmaceutical and biotechnology companies for over 14 years. He has practiced law at both large law firms and at Fortune 100 companies including Monsanto and DuPont. Prior to Inovio, Mr. Kim served as Senior Counsel to the gene discovery group at DuPont Company, where he provided legal counsel on a variety of patent issues and drafted and prosecuted patent applications related to DNA molecules and transgenic organisms.
Mr. Kim received a J.D. from Washington University School of Law in St. Louis, a M.S. in Biochemistry from the University of Illinois, and a B.S. in Chemistry from the Georgia Institute of Technology. He is licensed to practice law in the Commonwealth of Pennsylvania, State of Illinois, and is registered to practice before the U.S. Patent and Trademark Office.
Page 'Breadcrumb' Navigation